Drug Profile
Research programme: malaria vaccine - Maxygen
Alternative Names: Maxy-678; Maxy-MalariaLatest Information Update: 10 Jun 2013
Price :
$50
*
At a glance
- Originator Maxygen
- Class Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 10 Jun 2013 Discontinued - Preclinical for Malaria in USA (Parenteral)
- 18 Sep 2008 This malaria vaccine programme is available for licensing (http://www.maxygen.com)
- 20 Jun 2006 No development reported - Preclinical for Malaria in USA (Parenteral)